Eli Lilly (NYSE: LLY) has splashed out on a licensing and research collaboration in RNA interference (RNAi).
The US pharma major is to pay Boston biotech Dicerna Pharmaceuticals (Nasdaq: DRNA) $100 million upfront and an equity investment of $100 million, along with up to approximately $350 million per target in development and commercialization milestones, plus royalties.
Targets sought using Dicerna’s proprietary GalXC RNAi technology platform will be in the areas of cardio-metabolic disease, neurodegeneration and pain.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze